A	a	O	O	O	O
prospective	prospective	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
adverse	adverse	O	O	O	O
reactions	reactions	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
vancomycin	vancomycin	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
prospective	prospective	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
safety	safety	O	O	O	O
of	of	O	O	O	O
vancomycin	vancomycin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
conducted	conducted	O	O	O	O
in	in	O	O	O	O
54	54	O	O	O	O
consecutive	consecutive	O	O	O	O
patients	patients	O	O	O	O
over	over	O	O	O	O
a	a	O	O	O	O
16-month	16-month	O	O	O	O
period	period	O	O	O	O
.	.	O	O	O	O

Vancomycin	vancomycin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
curative	curative	O	O	O	O
in	in	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
43	43	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
proven	proven	O	O	O	O
infection	infection	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Drugs	drugs	O	O	O	O
were	were	O	O	O	O
ceased	ceased	O	O	O	O
in	in	O	O	O	O
six	six	O	O	O	O
patients	patients	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
adverse	adverse	O	O	O	O
reactions	reactions	O	O	O	O
;	;	O	O	O	O
in	in	O	O	O	O
three	three	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
vancomycin	vancomycin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
considered	considered	O	O	O	O
the	the	O	O	O	O
likely	likely	O	O	O	O
cause	cause	O	O	O	O
.	.	O	O	O	O

Reactions	reactions	O	O	O	O
included	included	O	O	O	O
thrombophlebitis	thrombophlebitis	O	O	OTHERS	I
(	(	O	O	O	O
20	20	O	O	O	O
of	of	O	O	O	O
54	54	O	O	O	O
patients	patients	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
rash	rash	O	DISEASE	OTHERS	I
(	(	O	O	O	O
4	4	O	O	O	O
of	of	O	O	O	O
54	54	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
(	(	O	O	O	O
4	4	O	O	O	O
of	of	O	O	O	O
50	50	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
of	of	O	O	O	O
50	50	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
ototoxicity	ototoxicity	O	DISEASE	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
of	of	O	O	O	O
11	11	O	O	O	O
patients	patients	O	O	O	O
tested	tested	O	O	O	O
by	by	O	O	O	O
audiometry	audiometry	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Thrombophlebitis	thrombophlebitis	O	O	OTHERS	I
occurred	occurred	O	O	O	O
only	only	O	O	O	O
with	with	O	O	O	O
infusion	infusion	O	O	O	O
through	through	O	O	O	O
peripheral	peripheral	O	O	O	O
cannulae	cannulae	O	O	O	O
;	;	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
and	and	O	O	O	O
ototoxicity	ototoxicity	O	DISEASE	OTHERS	I
were	were	O	O	O	O
confined	confined	O	O	O	O
to	to	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
an	an	O	O	O	O
aminoglycoside	aminoglycoside	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
vancomycin	vancomycin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
conclude	conclude	O	O	O	O
that	that	O	O	O	O
vancomycin	vancomycin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
administered	administered	O	O	O	O
appropriately	appropriately	O	O	O	O
,	,	O	O	O	O
constitutes	constitutes	O	O	O	O
safe	safe	O	O	O	O
,	,	O	O	O	O
effective	effective	O	O	O	O
therapy	therapy	O	O	O	O
for	for	O	O	O	O
infections	infections	O	DISEASE	OTHERS	I
caused	caused	O	O	O	O
by	by	O	O	O	O
susceptible	susceptible	O	O	O	O
bacteria	bacteria	O	O	O	O
.	.	O	O	O	O

